Search - tctmd.com

Displaying 261 - 280 of 318

Sort: Relevancy | Date

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

Presentation CHIP Seattle 2017

Inotropes and Drug Therapies for Shock: Data and Outcomes

Presenter: Sunil V. Rao

August 11, 2017

News Daily News

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Michael O'Riordan

August 08, 2017

News Daily News

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Michael O'Riordan

August 04, 2017

News Daily News

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Michael O'Riordan

August 01, 2017

News Conference News SCCT 2017

Coronary Calcium Scores in 2017: Useful, Yes, but Hard Outcomes Data Still Lacking

Yael L. Maxwell

July 13, 2017

News Daily News

Top-Line REVEAL Results Support Efficacy of CETP Inhibition, but Questions Abound

Todd Neale

June 27, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2017

Shelley Wood

June 01, 2017

News Daily News

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

L.A. McKeown

May 23, 2017

News Daily News

Long-term MI Risk Among Stable CAD Patients: Some Clues From CORONOR

Shelley Wood

April 24, 2017

News

Mortality and CVD Decline in Patients With Diabetes, but Biggest Strides Seen for Nonfatal Outcomes

Michael O'Riordan

April 13, 2017

News Conference News ACC 2017

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

Yael L. Maxwell

March 23, 2017

News Conference News ACC 2017

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

Yael L. Maxwell

March 17, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

News Conference News ACC 2017

Erectile Dysfunction Meds Linked to Fewer Death and HF Hospitalizations After MI

L.A. McKeown

March 09, 2017

News Daily News

Testing Testosterone: Two Studies Show Nothing to Promote Its Use Among Cardiovascular Patients

Yael L. Maxwell

February 24, 2017

News Daily News

‘Misalignment’ Exists Between What Concerns Patients and Physicians Most After PCI

Michael O'Riordan

February 13, 2017

News Daily News

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Michael O'Riordan

February 03, 2017

News Daily News

Meta-analysis Calls Into Question Strength of Guidance for RAS Blockade in Patients With Stable CAD

Todd Neale

January 19, 2017

Advertisement

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Inotropes and Drug Therapies for Shock: Data and Outcomes

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Coronary Calcium Scores in 2017: Useful, Yes, but Hard Outcomes Data Still Lacking

Top-Line REVEAL Results Support Efficacy of CETP Inhibition, but Questions Abound

TCTMD’s Top 10 Most Popular Stories for May 2017

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

Long-term MI Risk Among Stable CAD Patients: Some Clues From CORONOR

Mortality and CVD Decline in Patients With Diabetes, but Biggest Strides Seen for Nonfatal Outcomes

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Erectile Dysfunction Meds Linked to Fewer Death and HF Hospitalizations After MI

Testing Testosterone: Two Studies Show Nothing to Promote Its Use Among Cardiovascular Patients

‘Misalignment’ Exists Between What Concerns Patients and Physicians Most After PCI

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Meta-analysis Calls Into Question Strength of Guidance for RAS Blockade in Patients With Stable CAD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content